Research To Practice | Oncology Videos

Featuring perspectives from Drs Erika Hamilton, Sara Hurvitz, Ian Krop, Shanu Modi and Sara Tolaney, including the following topics: Optimizing the Management of Localized HER2-Positive Breast Cancer Introduction (0:00) Case: A woman in her mid 60s with pulmonary hypertension and triple-positive, node-positive infiltrating ductal carcinoma (IDC) after neoadjuvant TCHP and clinical complete remission — Susmitha Apuri, MD (4:31) Case: A woman in her early 60s with a 1.7-cm, triple-positive, clinically node-negative IDC — Ranju Gupta, MD (10:05) Dr Tolaney presentation (18:44) Current Considerations in the Treatment of HER2-Positive Metastatic Breast Cancer (mBC) Case: A woman in her early 60s with an 8-cm, ER-negative, PR-positive, HER2-positive IDC and positive nodes bilaterally after neoadjuvant TCHP and bilateral mastectomies with no residual disease — Henna Malik, MD (31:12) Case: A woman in her late 50s with Stage IIIA, ER/PR-negative, HER2-positive, node-positive IDC with residual disease after neoadjuvant TCHP and mastectomy — Laila Agrawal, MD ()35:29 Dr Krop presentation (42:56) Management of HER2-Positive Breast Cancer with CNS Metastases Case: A woman in her early 90s with "mild" dementia and ER/PR-negative, HER2 IHC 1+ IDC with symptomatic chest wall recurrence after neoadjuvant paclitaxel/trastuzumab and lumpectomy — Alan B Astrow, MD (54:54) Case: A woman in her late 40s with a triple-positive multifocal IDC with a gBRCA2 mutation and HER2-negative axillary nodes after neoadjuvant TCHP and bilateral mastectomies with significant response in the breast but 49 positive nodes — Zanetta S Lamar, MD (1:00:01) Dr Hamilton presentation (1:06:51) Recent Appreciation of HER2 Low as a Unique Disease Subset; Future Directions in the Management of HER2-Positive and HER2-Low Breast Cancer Cases: A premenopausal woman in her late 30s with a triple-positive IDC who develops brain metastases while receiving THP; A woman in her late 60s with an ER/PR-negative, HER2-positive IDC who develops brain metastases after first-line THP and second-line T-DM1 — Kelly Yap, MD & Rohit Gosain, MD (1:20:46) Case: A woman in her mid 60s with ER/PR-negative, HER2-positive mBC treated with paclitaxel/trastuzumab, then T-DXd on progression — Joanna Metzner-Sadurski, MD (1:29:40) Dr Modi presentation (1:40:51) Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy Case: A woman in her early 60s with recurrent triple-positive mBC whose disease converts to HER2-negative, PIK3CA-positive at the time of progression — Dhatri Kodali, MD (2:01:10) Dr Hurvitz presentation (2:05:08) CME information and select publications

Featuring a slide presentation and related discussion from Dr Thomas Herzog, including the following topics: Keys to evaluating genetics in patients with ovarian cancer (0:00) Clinical trials evaluating PARP inhibitor maintenance therapy for patients with newly diagnosed ovarian cancer responding to platinum-based chemotherapy (7:35) Current status of PARP inhibitor use in the care of patients with ovarian cancer (18:45) Ongoing studies evaluating the combination of PARP and immune checkpoint inhibitors (24:37) CME information and select publications

Featuring perspectives from Dr Thomas Herzog, including the following topics: Impact of PARP inhibitors (PARPi) on the care of patients with ovarian cancer (0:00) Clarifying the recent withdrawal of PARPi for treatment of recurrent or refractory ovarian cancer (4:13) Sequential use of PARPi for patients with advanced ovarian cancer (16:56) Case: Woman in her late 60s with BRCA wild type ovarian cancer (20:06) Case: Woman in her early 50s with somatic BRCA-positive high-grade serous ovarian cancer (39:22) Case: Woman in her mid 60s with BRCA wild type and homologous recombination-deficient endometroid ovarian cancer (44:02) CME information and select publications

Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer — Faculty Presentation 2: TROP2 and Other Investigational Targets for ADCs in Advanced NSCLC — Dr Alexander Spira CME information and select publications

Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer — Faculty Presentation 1: Targeting HER2 and HER3 with Antibody-Drug Conjugates (ADCs) in Non-Small Cell Lung Cancer (NSCLC) — Dr Helena Yu CME information and select publications

Featuring perspectives from Drs Alexander Spira and Helena Yu, including the following topics: Introduction What is an antibody-drug conjugate? (0:00) "HER2-Positive" Non-Small Cell Lung Cancer (NSCLC) Case: A woman in her mid 50s with HER2 insertion in exon 20 — Dr Yu (8:42) Targeting HER3 in NSCLC Case: A man in his early 60s with lung cancer with an EGFR mutation — Dr Yu (25:23) TROP2-Directed Treatment Case: A woman in her early 50s with lung cancer with a KRAS G12V mutation — Dr Spira (36:57) Case: A woman in her mid 60s with metastatic NSCLC and an EGFR exon 19 deletion — Dr Spira (39:32) Novel Agents Mechanism of action of tusamitamab ravtansine and telisotuzumab vedotin (54:15) CME information and select publications

Featuring perspectives from Dr S Vincent Rajkumar, including the following topics: Introduction: Requiem for Belantamab Mafodotin? Dawn of a New Era (0:00) Case: A man in his early 70s with multiregimen-refractory multiple myeloma (MM) receives idecabtagene vicleucel with Grade 1 cytokine release syndrome and persistent cytopenias — Jesús G Berdeja, MD (16:12) Case: A man in his mid 60s with multiregimen-refractory MM receives idecabtagene vicleucel with a 20-month response — Dr Berdeja (25:19) Case: A man in his late 50s with multiregimen-refractory MM received idecabtagene vicleucel in 2020 and is currently in complete remission — Natalie S Callander, MD (31:11) Case: A man in his early 60s with multiregimen-refractory MM receives the novel bispecific antibody WVT078 on a clinical trial — Dr Callander (41:02) Case: A man in his mid 70s with multiregimen-refractory MM receives teclistamab on a clinical trial — Dr Berdeja (51:21) CME information and select publications

Featuring a slide presentation and related discussion from Dr Omid Hamid, including the following topics: Current evolution in the care of patients with metastatic melanoma (0:00) Novel immunotherapeutic strategies for patients with untreated metastatic melanoma (1:47) Efficacy and safety of novel agents and combination treatments for patients with previously treated metastatic melanoma (16:28) Future directions in the care of patients with metastatic melanoma (25:13) CME information and select publications

Featuring an interview with Dr Omid Hamid, including the following topics: First-line treatment of metastatic melanoma (0:00) Triplet therapy for patients with BRAF-mutated metastatic melanoma (7:27) Case: A man in his mid 60s with previously untreated BRAF wild-type metastatic melanoma (15:44) Novel therapeutic strategies for patients with newly diagnosed melanoma (21:02) Immunotherapy strategies for second-line treatment of metastatic melanoma (29:25) Case: A man in his mid 40s with BRAF-mutated melanoma who experiences disease progression after treatment with ipilimumab and nivolumab (37:16) CME information and select publications

Featuring a slide presentation and related discussion from Dr Eric Sherman, including the following topics: Incidence and mortality of thyroid cancer and the thyroid cancer treatment pyramid (0:00) Available and emerging data with targeted therapies for thyroid cancer (9:01) Optimal genomic screening and selection of treatment for medullary thyroid cancer (26:58) CME information and select publications